| scholarly article | Q13442814 |
| P50 | author | Alan McClelland | Q47504204 |
| P2093 | author name string | Janet Cunningham | |
| Lan Feng | |||
| Laura M Sanftner | |||
| John R Forsayeth | |||
| Mohammad M Doroudchi | |||
| Brian M Suzuki | |||
| P2860 | cites work | Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors | Q45886179 |
| Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. | Q49109638 | ||
| Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion | Q71694555 | ||
| Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection | Q30923081 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| Gene therapy: promises and problems. | Q34101058 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Adeno-associated virus vectors can be efficiently produced without helper virus | Q34479933 | ||
| AAV-mediated gene transfer for hemophilia | Q34497332 | ||
| Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain | Q35000819 | ||
| Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy | Q35131227 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina | Q36439639 | ||
| The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. | Q39540612 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia | Q40672177 | ||
| Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 | ||
| Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression | Q40972848 | ||
| Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. | Q43660897 | ||
| Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. | Q43707952 | ||
| Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes | Q43892747 | ||
| Additional transduction events after subretinal readministration of recombinant adeno-associated virus | Q45744116 | ||
| Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). | Q45747007 | ||
| Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 | ||
| Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion | Q45784128 | ||
| P433 | issue | 3 | |
| P921 | main subject | striatum | Q1319792 |
| P304 | page(s) | 403-409 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. | |
| P478 | volume | 9 |
| Q61976265 | AAV for disorders of the CNS |
| Q40334450 | AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses |
| Q37275446 | AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters |
| Q58584630 | Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer |
| Q35892068 | Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates |
| Q40433968 | Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity |
| Q39076892 | Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates |
| Q43134453 | Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus |
| Q37398172 | Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain |
| Q30531601 | Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses |
| Q37399627 | Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys |
| Q33491357 | Controlled dissemination of AAV vectors in the primate brain |
| Q40380857 | Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats |
| Q36945745 | Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles |
| Q45865447 | Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo |
| Q42502571 | Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. |
| Q50541384 | Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum |
| Q37127238 | Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders |
| Q58913419 | Gene therapy for Parkinson's disease |
| Q37810994 | Gene therapy for Parkinson’s disease: where are we now and where are we going? |
| Q36983203 | Gene therapy for misfolding protein diseases of the central nervous system |
| Q41785441 | Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies |
| Q31023442 | Human gene therapy and imaging in neurological diseases |
| Q36498773 | Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions |
| Q47277616 | Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects |
| Q33374015 | Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential |
| Q39519818 | Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia |
| Q34228552 | Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties |
| Q38949089 | Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease. |
| Q34718452 | Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brain |
| Q36368045 | Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. |
| Q34762396 | SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. |
| Q33819946 | Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys |
| Q40383175 | Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response. |
| Q33713348 | Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. |
| Q38004089 | The advent of AAV9 expands applications for brain and spinal cord gene delivery |
| Q35341751 | The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. |
| Q45868778 | Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. |
| Q42450986 | Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response |
| Q36041623 | Viral vector-based reversible neuronal inactivation and behavioral manipulation in the macaque monkey |
| Q36960666 | Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. |
Search more.